NCT01081847View on ClinicalTrials.gov

Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

April 30, 2006

Conditions
Malaria, Vivax
Interventions
DRUG

Peptides (N,R&C) formulated in Montanide ISA 720

50 ug

DRUG

Peptides (N,R&C) formulated in Montanide ISA 51

50 ug

DRUG

Peptides (N,R&C) formulated in Montanide ISA 720

100 ug

DRUG

Peptides (N,R&C) formulated in Montanide ISA 51

100 ug

OTHER

Placebo

PLacebo: Isotonic saline solution

Trial Locations (2)

Unknown

Malaria Vaccine and Drug Testing Center, Santiago de Cali

Malaria Vaccine of Develepmente Center, Santiago de Cali

All Listed Sponsors
collaborator

Centro médico Imbanaco

UNKNOWN

collaborator

Asoclinic Inmunología Ltda.

INDUSTRY

lead

Malaria Vaccine and Drug Development Center

OTHER

NCT01081847 - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants | Biotech Hunter | Biotech Hunter